Case Details
- Citation: [2012] SGHC 35
- Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 16 February 2012
- Case Number: Originating Summons No 1418 of 2009
- Coram: Tay Yong Kwang J
- Judgment reserved: Yes (judgment date: 16 February 2012)
- Plaintiff/Applicant: Martek Biosciences Corporation
- Defendant/Respondent: Cargill International Trading Pte Ltd
- Counsel for Applicant: Dr Stanley Lai, SC and Vignesh Vaerhn (Allen & Gledhill LLP)
- Counsel for Respondent: Daniel Koh (instructed) (Eldan Law LLP) and Wendy Low Wei Ling (Rajah & Tann LLP)
- Tribunal appealed from: Deputy Registrar of Patents and Principal Assistant Registrar of Patents (IPOS)
- Patent at issue: Singapore Patent No. 42669 (“the Patent”)
- Patent title: “Arachidonic Acid and Methods for the Production and Use Thereof”
- Patent grant date: 30 March 1999
- Re-examination trigger: IPOS Hearing Officers’ intention to cause re-examination under s 80(2) of the Patents Act
- Re-examination report: Dated 24 October 2008; made available on 6 November 2008
- Proceedings before Tribunal: 9 to 12 February 2009
- Evidence and procedure: Evidence Act (Cap 97, 1997 Rev Ed) and Rules of Court (Cap 322, R5, 2006 Ed) applied
- Related prior decision: Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”) concerning another patent (Singapore Patent P-No. 49307)
- Judgment length: 17 pages, 9,976 words
- Statutes referenced (as stated in extract): Patents Act (Cap 221, 2005 Rev Ed) (“the Act”); Evidence Act (Cap 97, 1997 Rev Ed); Rules of Court (Cap 322, R5, 2006 Ed)
- Cases cited (as stated in metadata): [2012] SGHC 35
Summary
Martek Biosciences Corporation v Cargill International Trading Pte Ltd ([2012] SGHC 35) concerns an appeal from a decision of IPOS patent registrars that revoked Martek’s Singapore Patent No. 42669. The respondent had sought revocation on two main grounds: (i) that the invention was not patentable under s 80(1)(a) of the Patents Act, and (ii) that the patent was insufficient under s 80(1)(c) because the specification allegedly did not disclose the invention clearly and completely for it to be performed by a person skilled in the art.
On appeal, Tay Yong Kwang J allowed Martek’s appeal against the revocation decision. While the extract provided does not reproduce the entire reasoning, the judgment’s structure and the court’s express disposition indicate that the High Court found error in the Tribunal’s approach to validity—particularly in relation to how the prior art and the sufficiency/patentability requirements were applied to the amended claims. The court also dismissed the respondent’s appeal insofar as it related to certain aspects of the Tribunal’s decision.
What Were the Facts of This Case?
The applicant, Martek Biosciences Corporation, is a Delaware company. The respondent, Cargill International Trading Pte Ltd, is incorporated in Singapore. Martek was the proprietor of Singapore Patent No. 42669, entitled “Arachidonic Acid and Methods for the Production and Use Thereof”. The patent was granted by IPOS on 30 March 1999.
The patent relates to processes for producing arachidonic acid (“ARA”) containing oils, preferably oils free of eicosapentaneoic acid (“EPA”), and to compositions and uses of such oils. ARA is a long chain omega-6 polyunsaturated fatty acid (“PUFA”) important for human metabolism. The patent explains that humans cannot synthesize ARA de novo, so ARA must be obtained from diet, especially during infancy when growth is rapid. Human breast milk contains high ARA levels, and the patent aims to replicate those levels in infant formula.
Martek’s patent addresses a commercial and technical problem: many microbial species that produce ARA also produce significant quantities of EPA, and high EPA levels can depress the ability to form ARA from dietary linoleic acid. Thus, the invention prefers microbial strains that produce ARA with minimal EPA, and it contemplates achieving target ARA:EPA ratios (with preferred ratios of at least 5:1, more preferably at least 10:1, and ideally around 20:1). The patent also contemplates producing triglyceride oils and using them as additives for infant formula.
On 20 January 2006, Cargill filed an application to revoke the patent. The revocation grounds were that the invention was not patentable under s 80(1)(a) and that the patent was insufficient under s 80(1)(c). Martek responded by applying to amend the claims on 6 September 2006. The amendments were advertised in the Patents Journal on 30 October 2006 and were not opposed. The Tribunal held the amendments were allowable because they did not add matter or extend protection. Accordingly, the revocation proceedings proceeded on the basis of the amended claims.
What Were the Key Legal Issues?
The High Court had to determine whether the Tribunal was correct to revoke the patent on the grounds pleaded. The first legal issue was patentability under s 80(1)(a) of the Patents Act. In practice, this typically engages questions of whether the claimed invention lacks novelty and/or inventive step in light of the prior art, or otherwise fails to meet the statutory requirements for a patentable invention.
The second legal issue was sufficiency under s 80(1)(c). The statutory test requires that the specification disclose the invention clearly and completely so that a person skilled in the art can perform it. In biotechnology and chemical patents, sufficiency disputes often turn on whether the specification provides adequate guidance on critical parameters, such as strain selection, culture conditions, and how to achieve the claimed compositional outcomes (for example, the ARA:EPA ratio and the triglyceride form).
A further procedural and evidential issue also emerged: the Tribunal’s assessment of expert evidence, particularly the respondent’s expert testimony. The extract shows that the applicant attacked the credibility and relevance of one expert (Dr Puah), and the Tribunal expressed caution and ultimately did not rely heavily on that evidence. The High Court’s review therefore necessarily involved evaluating whether the Tribunal’s findings were properly grounded in the evidence and the correct legal standards.
How Did the Court Analyse the Issues?
The judgment begins by framing the appeal as the second appeal by Martek from IPOS. The first appeal concerned another patent and resulted in a High Court decision in Martek v Cargill (No 1) ([2011] 4 SLR 429). This context matters because the parties, subject matter, and evidential landscape were similar, and the High Court could draw on its prior reasoning about how to approach validity challenges in this technical field.
On the evidential front, the extract highlights a significant dispute about expert testimony. Dr Puah, one of the respondent’s experts, was criticised for lacking relevant expertise and for failing to understand key technical distinctions (such as total lipids versus fatty acids versus oil), as well as for not being knowledgeable about pH profiling and culture conditions, and for not understanding what a “fungal oil” is. The Tribunal indicated it was inclined to share the applicant’s general concerns and found that Dr Puah did not appear to possess the relevant expertise to assist confidently on the matters in question. Importantly, the High Court noted that it was not necessary to disregard Dr Puah’s evidence entirely because the Tribunal did not rely on it for its findings, and the respondent confirmed it was not relying on Dr Puah’s evidence, relying instead on Dr Nga’s evidence and the objective text of the prior art.
Turning to the substantive patent, the court summarised the essence of the invention: cultivation of Mortierella alpina under conditions yielding triglyceride oil with high ARA residues; harvesting biomass; extracting and recovering oil; and using it as an additive for infant formula. The patent’s technical purpose is to provide an economical method of producing ARA without concomitant EPA production, thereby avoiding the negative effects of EPA on ARA formation. The patent also emphasises target ARA:EPA ratios, reflecting a compositional achievement that is central to the claimed invention.
The prior art considered by the Tribunal included D1, D4, D7, and D10 as particularly significant. D1 is “Production of Arachidonic Acid by Mortierella alpina ATCC 3222” (Bajpai et al, 1991). D4 is a Japanese patent translated into English concerning an external preparation for skin. D7 is WO 92/13086 titled “Arachidonic Acid and methods of the production and use thereof” (1992). D10 is WO 94/28913 concerning methods and pharmaceutical compositions for treating neurological disorders. The High Court indicated that it would analyse the contents of the prior art when addressing validity, and the Tribunal’s summary at [100] was identified as a useful starting point.
Although the extract provided is truncated before the court’s full analysis of novelty/inventive step and sufficiency, the High Court’s approach can be inferred from its appellate posture and the way it dealt with expert evidence. The court’s reasoning likely involved (i) identifying the correct construction of the amended claims, (ii) comparing the claimed subject matter against the disclosures of the prior art documents, and (iii) assessing whether the Tribunal applied the correct legal tests for patentability and sufficiency. In sufficiency disputes, the court would also have considered whether the specification provided enough information to enable a skilled person to reproduce the claimed ARA:EPA ratios and triglyceride composition using the described microbial cultivation and extraction methods.
Further, the High Court’s express decision to allow Martek’s appeal suggests that the Tribunal’s findings on one or more of the statutory grounds were not sustainable. This may have involved misapprehension of the prior art’s disclosure, an overly rigid or incorrect approach to claim construction, or an evidential gap in establishing that the specification failed the sufficiency threshold. The court’s dismissal of the respondent’s appeal “insofar as it relates to certain aspects of the Decision” indicates that the respondent had also challenged parts of the Tribunal’s reasoning or findings, but those challenges did not succeed.
What Was the Outcome?
The High Court allowed Martek’s appeal against the Tribunal’s decision revoking Singapore Patent No. 42669. In practical terms, this means the patent was not revoked and remained in force (subject to any limited aspects dismissed in the respondent’s counter-appeal). The High Court therefore corrected the Tribunal’s approach to validity and restored the patent’s legal standing.
The court also dismissed the respondent’s appeal insofar as it related to certain aspects of the Tribunal’s decision. This indicates that while the respondent’s overall position (revocation) failed, some narrower issues raised by the respondent did not warrant appellate intervention.
Why Does This Case Matter?
This decision is significant for practitioners because it demonstrates the High Court’s willingness to scrutinise IPOS tribunal reasoning in patent revocation proceedings, particularly where technical evidence and claim construction are central. Biotechnology and chemical patents often turn on fine distinctions—such as what exactly is disclosed in the prior art, what a skilled person would understand, and whether the specification enables the claimed results. Martek v Cargill reinforces that appellate review will focus on whether the statutory requirements for patentability and sufficiency were properly applied to the amended claims.
From a litigation strategy perspective, the case also illustrates the importance of expert evidence quality and relevance. The Tribunal’s caution about Dr Puah’s expertise, and the respondent’s confirmation that it relied only on the other expert and objective prior art texts, shows how evidential credibility can affect the weight of technical testimony. Even where an expert is not fully persuasive, the tribunal and the court may still base findings on documentary prior art and the remaining expert evidence—yet the overall validity conclusion must still satisfy the statutory tests.
Finally, the case matters because it sits within a broader dispute between the same parties over related patents. The High Court’s reference to Martek v Cargill (No 1) suggests continuity in the legal and factual matrix. For researchers and counsel, this provides a roadmap for how the court approaches similar technical subject matter and how it treats prior art disclosures across multiple patents in the same family of disputes.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), in particular:
- Section 80(1)(a) (patentability / patentable invention requirement)
- Section 80(1)(c) (insufficiency / clear and complete disclosure)
- Section 80(2) (re-examination mechanism)
- Evidence Act (Cap 97, 1997 Rev Ed)
- Rules of Court (Cap 322, R5, 2006 Ed)
Cases Cited
- Martek Biosciences Corporation v Cargill International Trading [2011] 4 SLR 429 (“Martek v Cargill (No 1)”)
- [2012] SGHC 35 (this case)
Source Documents
This article analyses [2012] SGHC 35 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.